Demographics (2)
- sex - Gender of participant (phv00427506.v1.p1)
- SEX - Annotated Sex (phv00570423.v1.p1)
Disease Events (1)
- af_status - AF status (phv00427505.v1.p1)
Race and Ethnicity (1)
- race - Race of participant (phv00427507.v1.p1)
Other (14)
- ANALYTE_TYPE - Analyte Type (phv00427510.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00427509.v1.p1)
- CONSENT - Registered consent groups (Data Use Limitations (DUL)) as determined by submitters' Institutional Review Boards (IRB) or equivalent body. (phv00427500.v1.p1)
- Funding_Source - Project funding source (phv00427513.v1.p1)
- IS_TUMOR - Tumor status (phv00427511.v1.p1)
- SAMPLE_ID - Sample ID (phv00427508.v1.p1)
- SAMPLE_ID - Sample ID (phv00427503.v1.p1)
- SEQUENCING_CENTER - Name of the center which conducted sequencing (phv00427512.v1.p1)
- Study_Name - TOPMed-assigned short study name (1:1 with TOPMed phs number) (phv00427516.v1.p1)
- SUBJECT_ID - De-identified Subject ID (phv00427504.v1.p1)
- SUBJECT_ID - Subject ID (phv00427499.v1.p1)
- SUBJECT_ID - Subject ID (phv00427502.v1.p1)
- TOPMed_Phase - TOPMed Phase (phv00427514.v1.p1)
- TOPMed_Project - TOPMed Project that funded sequencing (phv00427515.v1.p1)